OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Cancer is 68. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)

Article	Citations
Cancer vaccines: the next immunotherapy frontier	337
Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer	280
Overcoming therapy resistance in EGFR-mutant lung cancer	245
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression	237
Cancer-associated fibroblasts in the single-cell era	225
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer	203
A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors	202
Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities	197
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma	191
Fatty acid synthesis is required for breast cancer brain metastasis	186
Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology	184
Artificial intelligence in histopathology: enhancing cancer research and clinical oncology	178
Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity	178
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology	175
Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity	167
The metabolic landscape of RAS-driven cancers from biology to therapy	163
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells	160
The cGAS–STING pathway and cancer	155
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer	147
Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial	144
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas	134
EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer	133
A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy	133
CD4+ T cells in cancer	133
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia	132

Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer	130
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer	127
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy	125
Translational advances in pancreatic ductal adenocarcinoma therapy	124
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma	116
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade	113
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity	113
The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response	113
Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients	110
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study	109
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis	106
Three-dimensional imaging mass cytometry for highly multiplexed molecular and cellular mapping of tissues and the tumor microenvironment	104
A systematic CRISPR screen defines mutational mechanisms underpinning signatures caused by replication errors and endogenous DNA damage	104
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity	103
The immuno-oncological challenge of COVID-19	101
Targeting public neoantigens for cancer immunotherapy	100
Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism	97
Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors	95
Emerging strategies for treating metastasis	94
A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets	93
Super enhancers define regulatory subtypes and cell identity in neuroblastoma	93
Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors	90
Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in glioblastoma	88
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy	82
The present and future of PI3K inhibitors for cancer therapy	82
Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy	81
ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1	81
Cancer cell plasticity during tumor progression, metastasis and response to therapy	81
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer	80
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer	79
Targeting PUS7 suppresses tRNA pseudouridylation and glioblastoma tumorigenesis	79
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia	79
Bone marrow NG2+/Nestin+ mesenchymal stem cells drive DTC dormancy via TGF-β2	78
Dysregulation and therapeutic targeting of RNA splicing in cancer	77
Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients	76
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer	76
Neutrophil oxidative stress mediates obesity-associated vascular dysfunction and metastatic transmigration	75
Engineering-enhanced CAR T cells for improved cancer therapy	74
GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision	74
Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma	72
Bystander T cells in cancer immunology and therapy	71
Radiation exposure elicits a neutrophil-driven response in healthy lung tissue that enhances metastatic colonization	70
The status of tumor mutational burden and immunotherapy	70
Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain	68
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets	68
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study	68